# Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

> **NCT01709500** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 249 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** LMT (atorvastatin, simvastatin, or rosuvastatin)
- **DRUG:** alirocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01709500
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-05
- **Final completion:** 2015-01
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2015-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709500, "Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01709500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*